Jonathan I Epstein

List of Publications by Year
in descending order

592 papers	53,121 citations	1099 112 h-index	2033 205 g-index
600 all docs	600 docs citations	600 times ranked	20537 citing authors

#	Article	IF	Citations
1	The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2005, 29, 1228-1242.	3.7	2,334
2	The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2016, 40, 244-252.	3.7	2,256
3	The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder. American Journal of Surgical Pathology, 1998, 22, 1435-1448.	3.7	1,417
4	Pathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable (Stage T1 c) Prostate Cancer. JAMA - Journal of the American Medical Association, 1994, 271, 368.	7.4	1,325
5	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. European Urology, 2016, 69, 428-435.	1.9	1,039
6	Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology, 2001, 58, 843-848.	1.0	943
7	LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 555-565.	1.8	939
8	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 2013, 37, 1469-1489.	3.7	922
9	Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer, 1993, 71, 3582-3593.	4.1	709
10	Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer. Journal of Urology, 2003, 169, 517-523.	0.4	691
11	Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years. Journal of Urology, 1994, 152, 1831-1836.	0.4	650
12	Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades. European Urology, 2012, 61, 1019-1024.	1.9	550
13	Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. Journal of Clinical Oncology, 2011, 29, 2185-2190.	1.6	545
14	Prognostic <scp>G</scp>leason grade grouping: data based on the modified <scp>G</scp>leason scoring system. BJU International, 2013, 111, 753-760.	2.5	540
15	Prediction of Progression Following Radical Prostatectomy. American Journal of Surgical Pathology, 1996, 20, 286-292.	3.7	532
16	Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 3379-3385.	1.6	454
17	Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. American Journal of Surgical Pathology, 2014, 38, 756-767.	3.7	439
18	An Update of the Gleason Grading System. Journal of Urology, 2010, 183, 433-440.	0.4	432

#	Article	IF	Citations
19	Prostate Needle Biopsies Containing Prostatic Intraepithelial Neoplasia or Atypical Foci Suspicious for Carcinoma: Implications for Patient Care. Journal of Urology, 2006, 175, 820-834.	0.4	372
20	Correlation of Prostate Needle Biopsy and Radical Prostatectomy Gleason Grade in Academic and Community Settings. American Journal of Surgical Pathology, 1997, 21, 566-576.	3.7	354
21	Influence of Capsular Penetration on Progression Following Radical Prostatectomy: A Study of 196 Cases with Long-Term Followup. Journal of Urology, 1993, 150, 135-141.	0.4	353
22	Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologist. Human Pathology, 2001, 32, 81-88.	2.0	334
23	Small Cell Carcinoma of the Prostate. American Journal of Surgical Pathology, 2008, 32, 65-71.	3.7	331
24	An updated prostate cancer staging nomogram (<scp>P</scp>artin tables) based on cases from 2006 to 2011. BJU International, 2013, 111, 22-29.	2.5	323
25	Positive Surgical Margins After Radical Prostatectomy: A Systematic Review and Contemporary Update. European Urology, 2014, 65, 303-313.	1.9	319
26	Is Tumor Volume an Independent Predictor of Progression Following Radical Prostatectomy? A Multivariate Analysis of 185 Clinical Stage B Adenocarcinomas of the Prostate with 5 Years of Followup. Journal of Urology, 1993, 149, 1478-1481.	0.4	314
27	Expectant Management of Prostate Cancer With Curative Intent: An Update of The Johns Hopkins Experience. Journal of Urology, 2007, 178, 2359-2365.	0.4	308
28	Do Adenocarcinomas of the Prostate With Gleason Score (GS)â‰¤6 Have the Potential to Metastasize to Lymph Nodes?. American Journal of Surgical Pathology, 2012, 36, 1346-1352.	3.7	302
29	Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology, 2000, 56, 823-827.	1.0	298
30	Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Modern Pathology, 2006, 19, 1528-1535.	5.5	298
31	Prognosis of Untreated Stage A1 Prostatic Carcinoma: A Study of 94 Cases with Extended Followup. Journal of Urology, 1986, 136, 837-839.	0.4	286
32	Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists. Human Pathology, 2001, 32, 74-80.	2.0	280
33	Mandatory second opinion surgical pathology at a large referral hospital. Cancer, 1999, 86, 2426-2435.	4.1	275
34	Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2014, 20, 890-903.	7.0	275
35	The Contemporary Concept of Significant Versus Insignificant Prostate Cancer. European Urology, 2011, 60, 291-303.	1.9	267
36	ERA SPECIFIC BIOCHEMICAL RECURRENCE-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2001, 166, 416-419.	0.4	266

#	Article	IF	Citations
37	NKX3.1 as a Marker of Prostatic Origin in Metastatic Tumors. American Journal of Surgical Pathology, 2010, 34, 1097-1105.	3.7	243
38	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Modern Pathology, 2011, 24, 48-57.	5.5	239
39	Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program. Journal of Clinical Oncology, 2010, 28, 2810-2816.	1.6	237
40	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Modern Pathology, 2011, 24, 6-15.	5.5	234
41	Contemporary Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2017, 41, e1-e7.	3.7	233
42	Genomic and phenotypic heterogeneity in prostate cancer. Nature Reviews Urology, 2021, 18, 79-92.	3.8	215
43	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Modern Pathology, 2011, 24, 16-25.	5.5	214
44	Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care. European Urology, 2013, 63, 214-230.	1.9	214
45	Characteristics of insignificant clinical T1c prostate tumors. Cancer, 2004, 101, 2001-2005.	4.1	213
46	The Utility of Basal Cellâ€"Specific Anti-Cytokeratin Antibody (34Î²E12) in the Diagnosis of Prostate Cancer. American Journal of Surgical Pathology, 1995, 19, 251-260.	3.7	208
47	Gleason Score 2â€“4 Adenocarcinoma of the Prostate on Needle Biopsy. American Journal of Surgical Pathology, 2000, 24, 477-478.	3.7	205
48	EXPECTANT MANAGEMENT OF NONPALPABLE PROSTATE CANCER WITH CURATIVE INTENT: PRELIMINARY RESULTS. Journal of Urology, 2002, 167, 1231-1234.	0.4	203
49	Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagnostic Pathology, 2016, 11, 25.	2.0	201
50	Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies. Journal of Urology, 2014, 192, 1081-1087.	0.4	196
51	The Prognostic Significance of Tertiary Gleason Patterns of Higher Grade in Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 2000, 24, 563-569.	3.7	195
52	Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scandinavian Journal of Urology and Nephrology, 2005, 39, 34-63.	1.4	194
53	Predicting Cancer Following a Diagnosis of High-Grade Prostatic Intraepithelial Neoplasia on Needle Biopsy. American Journal of Surgical Pathology, 2001, 25, 1079-1085.	3.7	192
54	Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma. American Journal of Surgical Pathology, 2007, 31, 1246-1255.	3.7	192

#	Article	IF	Citations
55	Intraductal Carcinoma of the Prostate Without Invasive Carcinoma on Needle Biopsy: Emphasis on Radical Prostatectomy Findings. Journal of Urology, 2010, 184, 1328-1333.	0.4	192
56	ERG gene rearrangements are common in prostatic small cell carcinomas. Modern Pathology, 2011, 24, 820-828.	5.5	191
57	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Modern Pathology, 2011, 24, 26-38.	5.5	190
58	Potency Following Radical Prostatectomy with Wide Unilateral Excision of the Neurovascular Bundle. Journal of Urology, 1987, 138, 823-827.	0.4	189
59	Sarcomas and Related Proliferative Lesions of Specialized Prostatic Stroma. American Journal of Surgical Pathology, 1998, 22, 148-162.	3.7	188
60	Small cell carcinoma of the prostate. Nature Reviews Urology, 2014, 11, 213-219.	3.8	187
61	Use of Keratin 903 as an Adjunct in the Diagnosis of Prostate Carcinoma. American Journal of Surgical Pathology, 1989, 13, 389-396.	3.7	181
62	Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Human Pathology, 1996, 27, 683-687.	2.0	180
63	Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate. , 1997, 79, 772-779.		179
64	Clinical and Cost Impact of Second-opinion Pathology. American Journal of Surgical Pathology, 1996, 20, 851-857.	3.7	174
65	USE OF REPEAT SEXTANT AND TRANSITION ZONE BIOPSIES FOR ASSESSING EXTENT OF PROSTATE CANCER. Journal of Urology, 1997, 158, 1886-1890.	0.4	173
66	Evaluation of Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 1992, 16, 315-324.	3.7	169
67	Morphometric Measurement of Tumor Volume and Per Cent of Gland Involvement as Predictors of Pathological Stage in Clinical Stage B Prostate Cancer. Journal of Urology, 1989, 141, 341-345.	0.4	168
68	Prospective Evaluation of Men With Stage T1C Adenocarcinoma of the Prostate. Journal of Urology, 1997, 157, 2206-2209.	0.4	167
69	The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017, 70, 335-346.	2.9	165
70	Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Human Pathology, 1993, 24, 624-629.	2.0	164
71	Relationship Between Perineural Tumor Invasion on Needle Biopsy and Radical Prostatectomy Capsular Penetration in Clinical Stage B Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 1993, 17, 336-341.	3.7	164
72	Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. Journal of Cellular Biochemistry, 2004, 91, 459-477.	2.6	164

#	Article	IF	Citations
73	Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer?. Journal of Clinical Oncology, 2012, 30, 4294-4296.	1.6	162
74	Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology, 2005, 66, 356-360.	1.0	161
75	Management of Stage D1 Adenocarcinoma of the Prostate: The Johns Hopkins Experience 1974 to 1987. Journal of Urology, 1990, 144, 1425-1432.	0.4	160
76	Best Practices Recommendations in the Application of Immunohistochemistry in the Prostate. American Journal of Surgical Pathology, 2014, 38, e6-e19.	3.7	157
77	Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clinical Cancer Research, 2015, 21, 2591-2600.	7.0	157
78	Specialized Stromal Tumors of the Prostate: A Clinicopathologic Study of 50 Cases. American Journal of Surgical Pathology, 2006, 30, 694-704.	3.7	156
79	Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology, 2000, 56, 283-288.	1.0	148
80	Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology, 1999, 53, 351-355.	1.0	147
81	ALK-1 Expression in Inflammatory Myofibroblastic Tumor of the Urinary Bladder. American Journal of Surgical Pathology, 2004, 28, 1609-1614.	3.7	145
82	Brain biocompatibility of a biodegradable, controlled-release polymer in rats. Journal of Biomedical Materials Research Part B, 1989, 23, 253-266.	3.1	144
83	Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer, 1986, 57, 111-119.	4.1	143
84	The World Health Organization 2016 classification of testicular nonâ€germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017, 70, 513-521.	2.9	143
85	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	2.5	143
86	Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia. American Journal of Surgical Pathology, 1995, 19, 873-886.	3.7	142
87	THE PATHOLOGICAL INTERPRETATION AND SIGNIFICANCE OF PROSTATE NEEDLE BIOPSY FINDINGS: IMPLICATIONS AND CURRENT CONTROVERSIES. Journal of Urology, 2001, 166, 402-410.	0.4	140
88	Nonâ€invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathology International, 2010, 60, 1-8.	1.3	140
89	Spindle cell lesions of the adult prostate. Modern Pathology, 2007, 20, 148-158.	5.5	139
90	Mutinous adenocarcinoma of the prostate gland. American Journal of Surgical Pathology, 1985, 9, 299-308.	3.7	138

#	Article	IF	Citations
91	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	5.5	138
92	Ductal Adenocarcinoma of the Prostate Diagnosed on Needle Biopsy. American Journal of Surgical Pathology, 1999, 23, 1471.	3.7	138
93	Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. European Urology, 2020, 77, 675-682.	1.9	137
94	Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Modern Pathology, 2014, 27, 875-886.	5.5	136
95	Evaluation of Radical Prostatectomy Capsular Margins of Resection. American Journal of Surgical Pathology, 1990, 14, 626-632.	3.7	133
96	Radical Prostatectomy for Impalpable Prostate Cancer: The Johns Hopkins Experience With Tumors Found on Transurethral Resection (Stages T1a and T1b) and on Needle Biopsy (Stage T1c). Journal of Urology, 1994, 152, 1721-1729.	0.4	133
97	Florid von Brunn Nests Mimicking Urothelial Carcinoma. American Journal of Surgical Pathology, 2003, 27, 1243-1252.	3.7	131
98	Radical Prostatectomy Findings in Patients in Whom Active Surveillance of Prostate Cancer Fails. Journal of Urology, 2009, 182, 2274-2279.	0.4	131
99	Low-grade myxoid renal epithelial neoplasms with distal nephron differentiation. Human Pathology, 2001, 32, 506-512.	2.0	129
100	Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Modern Pathology, 2013, 26, 587-603.	5.5	129
101	EFFECTS OF A SAW PALMETTO HERBAL BLEND IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2000, 163, 1451-1456.	0.4	128
102	Expression and Diagnostic Utility of Alpha-Methylacyl-CoA-Racemase (P504S) in Foamy Gland and Pseudohyperplastic Prostate Cancer. American Journal of Surgical Pathology, 2003, 27, 772-778.	3.7	128
103	Ability of Sextant Biopsies to Predict Radical Prostatectomy Stage. Urology, 1998, 51, 759-764.	1.0	127
104	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Modern Pathology, 2011, 24, 39-47.	5.5	127
105	Pathological Examination of Radical Prostatectomy Specimens in Men with Very Low Risk Disease at Biopsy Reveals Distinct Zonal Distribution of Cancer in Black American Men. Journal of Urology, 2014, 191, 60-67.	0.4	127
106	Expanding the Histologic Spectrum of Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. American Journal of Surgical Pathology, 2006, 30, 1554-1560.	3.7	125
107	Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 2008, 32, 1503-1512.	3.7	123
108	PAX8 (+)/p63 (â˜) Immunostaining Pattern in Renal Collecting Duct Carcinoma (CDC). American Journal of Surgical Pathology, 2010, 34, 965-969.	3.7	123

#	Article	IF	Citations
109	MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research, 2017, 23, 6863-6874.	7.0	122
110	Prospective Evaluation of 99mTc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. European Urology, 2016, 69, 413-416.	1.9	121
111	Î±-Methylacyl-CoA Racemase. American Journal of Surgical Pathology, 2003, 27, 1128-1133.	3.7	120
112	Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. Journal of Urology, 2010, 183, 534-538.	0.4	119
113	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	5.5	118
114	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	2.5	117
115	How Often Does Alpha-Methylacyl-CoA-Racemase Contribute to Resolving an Atypical Diagnosis on Prostate Needle Biopsy Beyond That Provided by Basal Cell Markers?. American Journal of Surgical Pathology, 2004, 28, 239-243.	3.7	116
116	Association of [â^'2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer. Journal of Urology, 2012, 188, 1131-1136.	0.4	115
117	Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scandinavian Journal of Urology and Nephrology, 2005, 39, 20-33.	1.4	114
118	Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Modern Pathology, 2007, 20, 828-834.	5.5	114
119	Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology, 2019, 74, 135-145.	2.9	114
120	Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland. Archives of Pathology and Laboratory Medicine, 2009, 133, 1568-1576.	2.5	114
121	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. American Journal of Surgical Pathology, 2016, 40, 1457-1472.	3.7	112
122	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. American Journal of Surgical Pathology, 2010, 34, 1367-1376.	3.7	111
123	UROTHELIAL NEOPLASMS IN PATIENTS 20 YEARS OR YOUNGER: A CLINICOPATHOLOGICAL ANALYSIS USING THE WORLD HEALTH ORGANIZATION 2004 BLADDER CONSENSUS CLASSIFICATION. Journal of Urology, 2005, 174, 1976-1980.	0.4	110
124	Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Modern Pathology, 2004, 17, 307-315.	5.5	109
125	Update on the Gleason Grading System for Prostate Cancer. Advances in Anatomic Pathology, 2006, 13, 57-59.	4.3	108
126	Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer, 1992, 70, 161-168.	4.1	107

#	Article	IF	Citations
127	Correlation Of Minute (0.5 MM or Less) Focus of Prostate Adenocarcinoma On Needle Biopsy With Radical Prostatectomy Specimen: Role of Prostate Specific Antigen Density. Journal of Urology, 2003, 170, 370-372.	0.4	107
128	Sarcomatoid Carcinoma of the Prostate: A Study of 42 Cases. American Journal of Surgical Pathology, 2006, 30, 1316-1321.	3.7	107
129	Diagnostic Approach to Eosinophilic Renal Neoplasms. Archives of Pathology and Laboratory Medicine, 2014, 138, 1531-1541.	2.5	106
130	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	5.5	106
131	Influence of Wide Excision of the Neurovascular Bundle(s) on Prognosis in Men with Clinically Localized Prostate Cancer with Established Capsular Penetration. Journal of Urology, 1993, 150, 142-146.	0.4	105
132	Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology, 1997, 49, 367-373.	1.0	103
133	Risk of Prostate Cancer on First Re-Biopsy Within 1 Year Following a Diagnosis of High Grade Prostatic Intraepithelial Neoplasia is Related to the Number of Cores Sampled. Journal of Urology, 2006, 175, 121-124.	0.4	101
134	High-grade Prostatic Intraepithelial Neoplasialike Ductal Adenocarcinoma of the Prostate: A Clinicopathologic Study of 28 Cases. American Journal of Surgical Pathology, 2008, 32, 1060-1067.	3.7	101
135	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydrataseâ€"deficient Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 279-292.	3.7	101
136	Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. , 1999, 39, 298-304.		100
137	A Contemporary Study Correlating Prostate Needle Biopsy and Radical Prostatectomy Gleason Score. Journal of Urology, 2008, 179, 1335-1339.	0.4	100
138	Prostatic Carcinoma with Abundant Xanthomatous Cytoplasm. American Journal of Surgical Pathology, 1996, 20, 419-426.	3.7	100
139	Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 169-178.	3.7	99
140	Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations. American Journal of Surgical Pathology, 2018, 42, 1166-1181.	3.7	98
141	Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. European Urology, 2010, 58, 851-864.	1.9	96
142	Prognostic Factors in Men with Stage D1 Prostate Cancer: Identification of Patients Less Likely to Have Prolonged Survival After Radical Prostatectomy. Journal of Urology, 1994, 152, 1077-1081.	0.4	95
143	The Role of P501S and PSA in the Diagnosis of Metastatic Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2007, 31, 1351-1355.	3.7	95
144	Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases. American Journal of Surgical Pathology, 2008, 32, 461-467.	3.7	95

#	Article	IF	Citations
145	Multiparametric magnetic resonance imaging findings in men with lowâ€risk prostate cancer followed using active surveillance. BJU International, 2013, 111, 1037-1045.	2.5	95
146	Contemporary Grading for Prostate Cancer: Implications for Patient Care. European Urology, 2013, 63, 892-901.	1.9	95
147	Biopsy Criteria for Determining Appropriateness for Active Surveillance inÂtheÂModern Era. Urology, 2014, 83, 869-874.	1.0	95
148	Osteoclast-rich undifferentiated carcinomas of the urinary tract. Modern Pathology, 2006, 19, 161-171.	5.5	94
149	The Significance of Positive Surgical Margin in Areas of Capsular Incision in Otherwise Organ Confined Disease at Radical Prostatectomy. Journal of Urology, 2007, 178, 1306-1310.	0.4	94
150	The plasmacytoid carcinoma of the bladderâ€"rare variant of aggressive urothelial carcinoma. International Journal of Cancer, 2011, 129, 346-354.	5.1	94
151	Individual and cumulative effect of prostate cancer riskâ€associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate, 2009, 69, 1195-1205.	2.3	93
152	Treatment decisionâ€making for localized prostate cancer: What younger men choose and why. Prostate, 2012, 72, 58-64.	2.3	93
153	Increasing Incidence of Minimal Residual Cancer In Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 1997, 21, 174-178.	3.7	93
154	Reâ€evaluation of 33 â€˜unclassifiedâ€™ eosinophilic renal cell carcinomas in young patients. Histopathology, 2018, 72, 588-600.	2.9	92
155	Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy. American Journal of Surgical Pathology, 2008, 32, 468-472.	3.7	91
156	Workgroup 5: Assessment of prostate carcinoma in core needle biopsy--Definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer, 1996, 78, 376-381.	4.1	90
157	Can Basal Cells Be Seen in Adenocarcinoma of the Prostate?. American Journal of Surgical Pathology, 2002, 26, 1151-1160.	3.7	90
158	Gleason Score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference in Gleason Scores 4 3 and 3 4 Independent of the Number of Involved Cores?. Journal of Urology, 2002, 167, 2440-2442.	0.4	90
159	The Prognostic Significance of Tertiary Gleason Pattern 5 in Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 2004, 28, 394-398.	3.7	90
160	Immunohistochemical Antibody Cocktail Staining (p63/HMWCK/AMACR) of Ductal Adenocarcinoma and Gleason Pattern 4 Cribriform and Noncribriform Acinar Adenocarcinomas of the Prostate. American Journal of Surgical Pathology, 2007, 31, 889-894.	3.7	89
161	Precursor lesions to prostatic adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 1-16.	2.8	89
162	Pathological Outcomes in Men with Low Risk and Very Low Risk Prostate Cancer: Implications on the Practice of Active Surveillance. Journal of Urology, 2013, 190, 1218-1223.	0.4	89

#	Article	IF	Citations
163	Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. International Journal of Cancer, 2000, 89, 514-518.	5.1	88
164	Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a highâ€risk cohort of men with negative initial prostate biopsies. BJU International, 2012, 110, 56-62.	2.5	88
165	Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer. Cancer, 1984, 54, 1666-1671.	4.1	87
166	Small High Grade Adenocarcinoma of the Prostate in Radical Prostatectomy Specimens Performed for Nonpalpable Disease: Pathogenetic and Clinical Implications. Journal of Urology, 1994, 151, 1587-1592.	0.4	87
167	Widespread High-grade Prostatic Intraepithelial Neoplasia on Prostatic Needle Biopsy: A Significant Likelihood of Subsequently Diagnosed Adenocarcinoma. American Journal of Surgical Pathology, 2006, 30, 1184-1188.	3.7	87
168	Tertiary Gleason Patterns and Biochemical Recurrence After Prostatectomy: Proposal for a Modified Gleason Scoring System. Journal of Urology, 2009, 182, 1364-1370.	0.4	87
169	A web-based tutorial improves practicing pathologists' Gleason grading of images of prostate carcinoma specimens obtained by needle biopsy. Cancer, 2000, 89, 1818-1823.	4.1	86
170	High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy. American Journal of Surgical Pathology, 2004, 28, 629-633.	3.7	86
171	Prediction of pathological stage based on clinical stage, serum prostateâ€specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. BJU International, 2017, 119, 676-683.	2.5	86
172	CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture. , 1998, 34, 162-168.		85
173	Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy. American Journal of Surgical Pathology, 2008, 32, 1532-1539.	3.7	85
174	A Contemporary Update on Pathology Reporting for Prostate Cancer: Biopsy and Radical Prostatectomy Specimens. European Urology, 2012, 62, 20-39.	1.9	85
175	Does High Grade Prostatic Intraepithelial Neoplasia Result in Elevated Serum Prostate Specific Antigen levels?. Journal of Urology, 1993, 150, 386-389.	0.4	84
176	DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. Journal of Urology, 1998, 160, 97-101.	0.4	84
177	Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy. Urology, 1998, 52, 803-807.	1.0	84
178	Prostate cancer grading: a decade after the 2005 modified system. Modern Pathology, 2018, 31, 47-63.	5.5	83
179	Do Close but Negative Margins in Radical Prostatectomy Specimens Increase the Risk of Postoperative Progression?. Journal of Urology, 1997, 157, 241-243.	0.4	82
180	Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. Human Pathology, 2001, 32, 494-499.	2.0	82

#	Article	IF	Citations
181	Prognostic Significance of Tumor Volume in Radical Prostatectomy and Needle Biopsy Specimens. Journal of Urology, 2011, 186, 790-797.	0.4	82
182	Large Nested Variant of Urothelial Carcinoma. American Journal of Surgical Pathology, 2011, 35, 1337-1342.	3.7	82
183	DEDIFFERENTIATION OF PROSTATE CANCER GRADE WITH TIME IN MEN FOLLOWED EXPECTANTLY FOR STAGE T1C DISEASE. Journal of Urology, 2001, 166, 1688-1691.	0.4	81
184	Atypical Basal Cell Hyperplasia of the Prostate. American Journal of Surgical Pathology, 1992, 16, 1205-1214.	3.7	80
185	Extensively Necrotic Cystic Renal Cell Carcinoma. American Journal of Surgical Pathology, 2000, 24, 988-995.	3.7	80
186	Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology, 2001, 57, 1112-1116.	1.0	80
187	PREDICTION OF EXTRAPROSTATIC EXTENSION IN THE NEUROVASCULAR BUNDLE BASED ON PROSTATE NEEDLE BIOPSY PATHOLOGY, SERUM PROSTATE SPECIFIC ANTIGEN AND DIGITAL RECTAL EXAMINATION. Journal of Urology, 2005, 173, 450-453.	0.4	80
188	Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. Human Pathology, 2010, 41, 594-601.	2.0	80
189	Advanced small cell carcinoma of the bladder successful treatment with combined radical cystoprostatectomy and adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer, 1990, 65, 1928-1936.	4.1	79
190	Extended Followup of the Influence of Wide Excision of the Neurovascular Bundle(s) on Prognosis in Men with Clinically Localized Prostate Cancer and Extensive Capsular Perforation. Journal of Urology, 1996, 156, 454-458.	0.4	79
191	Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology, 1999, 54, 791-795.	1.0	78
192	Distinguishing Nested Variants of Urothelial Carcinoma From Benign Mimickers by TERT Promoter Mutation. American Journal of Surgical Pathology, 2015, 39, 127-131.	3.7	78
193	High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Human Pathology, 2001, 32, 389-395.	2.0	77
194	Prognostic Significance of Gleason Score Discrepancies between Needle Biopsy and Radical Prostatectomy. European Urology, 2008, 53, 767-776.	1.9	77
195	Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology, 2004, 64, 551-555.	1.0	76
196	Prostate Cancer Early Detection, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1211-1219.	4.9	76
197	Frequent Loss of Chromosome Arms 8p and 13q in Collecting Duct Carcinoma (CDC) of the Kidney. Genes Chromosomes and Cancer, 1995, 12, 76-80.	2.8	75
198	Gleason 6 Prostate Cancer: Translating Biology into Population Health. Journal of Urology, 2015, 194, 626-634.	0.4	75

#	Article	IF	Citations
199	The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. European Urology, 2017, 71, 174-180.	1.9	75
200	Risk score predicts highâ€grade prostate cancer in DNAâ€methylation positive, histopathologically negative biopsies. Prostate, 2016, 76, 1078-1087.	2.3	74
201	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2016, 140, 1140-1152.	2.5	74
202	Intraoperative Sonography for the Evaluation and Management of Renal Tumors: Experience with 100 Patients. Journal of Urology, 1995, 154, 1676-1680.	0.4	73
203	Prognostic Significance of Paneth Cell-like Neuroendocrine Differentiation in Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2006, 30, 980-985.	3.7	73
204	Natural History of Pathologically Organ-Confined (pT2), Gleason Score 6 or Less, Prostate Cancer After Radical Prostatectomy. Urology, 2008, 72, 172-176.	1.0	73
205	Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma. American Journal of Surgical Pathology, 2015, 39, 1383-1389.	3.7	73
206	Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. Urology, 1995, 45, 981-986.	1.0	72
207	Utility of immunohistochemistry for Î±-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Human Pathology, 2004, 35, 1272-1278.	2.0	72
208	Primary Mucin-producing Urothelial-type Adenocarcinoma of Prostate: Report of 15 Cases. American Journal of Surgical Pathology, 2007, 31, 1323-1329.	3.7	72
209	Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?. Urology, 2001, 58, 746-751.	1.0	71
210	Can Prostate Specific Antigen Derivatives and Pathological Parameters Predict Significant Change in Expectant Management Criteria for Prostate Cancer?. Journal of Urology, 2003, 170, 2274-2278.	0.4	71
211	Small Glandular Proliferations on Needle Biopsies. American Journal of Surgical Pathology, 2005, 29, 874-880.	3.7	71
212	Extent of Extraprostatic Extension Independently Influences Biochemical Recurrence-free Survival: Evidence for Further pT3 Subclassification. Urology, 2015, 85, 161-164.	1.0	71
213	Relationship of severe dysplasia to Stage B adenocarcinoma of the prostate. Cancer, 1990, 65, 2328-2337.	4.1	70
214	Pseudohyperplastic Prostatic Adenocarcinoma on Needle Biopsy and Simple Prostatectomy. American Journal of Surgical Pathology, 2000, 24, 1039-1046.	3.7	70
215	A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy. Journal of Urology, 2011, 185, 1691-1697.	0.4	70
216	Perineural Invasion, Mucinous Fibroplasia, and Glomerulations. American Journal of Surgical Pathology, 1999, 23, 918.	3.7	70

#	Article	IF	Citations
217	Correlation of Ki-67 and p53 With the New World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Archives of Pathology and Laboratory Medicine, 2001, 125, 646-651.	2.5	70
218	Frozen Section Detection of Lymph Node Metastases in Prostatic Carcinoma: Accuracy in Grossly Uninvolved Pelvic Lymphadenectomy Specimens. Journal of Urology, 1986, 136, 1234-1237.	0.4	69
219	Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Human Pathology, 2009, 40, 471-477.	2.0	69
220	Gleason Score 7 Adenocarcinoma of the Prostate With Lymph Node Metastases: Analysis of 184 Radical Prostatectomy Specimens. Archives of Pathology and Laboratory Medicine, 2013, 137, 610-617.	2.5	69
221	PSA AND PAP AS IMMUNOHISTOCHEMICAL MARKERS IN PROSTATE CANCER. Urologic Clinics of North America, 1993, 20, 757-770.	1.8	69
222	Clear Cell Papillary Cystadenoma of the Epididymis and Mesosalpinx. American Journal of Surgical Pathology, 2005, 29, 520-523.	3.7	68
223	The Value of Mandatory Second Opinion Pathology Review of Prostate Needle Biopsy Interpretation Before Radical Prostatectomy. Journal of Urology, 2010, 184, 126-130.	0.4	68
224	Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Human Pathology, 1986, 17, 939-942.	2.0	67
225	Comparison of Gene Expression Profiles in Tubulocystic Carcinoma and Collecting Duct Carcinoma of the Kidney. American Journal of Surgical Pathology, 2009, 33, 1103-1106.	3.7	67
226	The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?. Critical Reviews in Oncology/Hematology, 2003, 47, 83-89.	4.4	66
227	Should Intervening Benign Tissue Be Included in the Measurement of Discontinuous Foci of Cancer on Prostate Needle Biopsy? Correlation With Radical Prostatectomy Findings. American Journal of Surgical Pathology, 2011, 35, 1351-1355.	3.7	66
228	Low-Grade Papillary Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of a Postâ€“World Health Organization/International Society of Urological Pathology Classification Cohort From a Single Academic Center. Archives of Pathology and Laboratory Medicine, 2010, 134, 1160-1163.	2.5	65
229	Papillary Urothelial Hyperplasia. American Journal of Surgical Pathology, 1996, 20, 1481-1488.	3.7	63
230	Relationship of severe dysplasia to Stage A (incidental) adenocarcinoma of the prostate. Cancer, 1990, 65, 2321-2327.	4.1	62
231	Adenocarcinoma of the Prostate with Atrophic Features. American Journal of Surgical Pathology, 1997, 21, 289-295.	3.7	62
232	Should each core with prostate cancer be assigned a separate gleason score?. Human Pathology, 2003, 34, 911-914.	2.0	61
233	Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer, 2004, 100, 1646-1649.	4.1	61
234	Residual Tumor Potentially Left Behind After Local Ablation Therapy in Prostate Adenocarcinoma. Journal of Urology, 2008, 179, 2203-2206.	0.4	61

#	Article	IF	Citations
235	Ureteral Frozen Section Analysis During Cystectomy: A Reassessment. Journal of Urology, 1996, 155, 1218-1220.	0.4	59
236	Fibromyxoid Nephrogenic Adenoma: A Newly Recognized Variant Mimicking Mucinous Adenocarcinoma. American Journal of Surgical Pathology, 2007, 31, 1231-1237.	3.7	59
237	Polypoid/Papillary Cystitis: A Series of 41 Cases Misdiagnosed as Papillary Urothelial Neoplasia. American Journal of Surgical Pathology, 2008, 32, 758-764.	3.7	59
238	Interobserver Variability in Histologic Evaluation of Radical Prostatectomy Between Central and Local Pathologists: Findings of TAX 3501 Multinational Clinical Trial. Urology, 2011, 77, 1155-1160.	1.0	59
239	Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?. American Journal of Surgical Pathology, 2015, 39, 1621-1634.	3.7	59
240	The Inability of Adrenal Androgens to Stimulate the Adult Human Prostate: An Autopsy Evaluation of Men with Hypogonadotropic Hypogonadism and Panhypopituitarism. Journal of Urology, 1986, 136, 1030-1034.	0.4	58
241	GATA-3 Immunohistochemistry in the Differential Diagnosis of Adenocarcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2013, 37, 1756-1760.	3.7	58
242	Bioimpedance: Novel use of a minimally invasive technique for cancer localization in the intact prostate. , 1999, 39, 213-218.		57
243	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2â€“ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	5.5	57
244	Pleomorphic Giant Cell Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2006, 30, 1254-1259.	3.7	56
245	Gleason Score 7 Prostate Cancer on Needle Biopsy: Relation of Primary Pattern 3 or 4 to Pathological Stage and Progression After Radical Prostatectomy. Journal of Urology, 2011, 186, 1286-1290.	0.4	56
246	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clinical Cancer Research, 2015, 21, 5619-5629.	7.0	56
247	In Situ Adenocarcinoma of the Bladder. American Journal of Surgical Pathology, 2001, 25, 892-899.	3.7	55
248	Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017, 72, 238-249.	1.9	55
249	Genetic Alterations in Urinary Bladder Carcinosarcoma: Evidence of a Common Clonal Origin. European Urology, 2000, 37, 350-357.	1.9	54
250	Partial Atrophy in Prostate Needle Cores. American Journal of Surgical Pathology, 1998, 22, 440-445.	3.7	54
251	Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage. Cancer, 1990, 65, 1021-1027.	4.1	52
252	Current practice of Gleason grading among genitourinary pathologists. Human Pathology, 2005, 36, 5-9.	2.0	52

#	Article	IF	Citations
253	Expanded Criteria to Identify Men Eligible for Active Surveillance of Low Risk Prostate Cancer at Johns Hopkins: A Preliminary Analysis. Journal of Urology, 2013, 190, 2033-2038.	0.4	52
254	Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy. JAMA Oncology, 2018, 4, 89.	7.1	52
255	The World Health Organisation 2016 classification of penile carcinomas: a review and update from the International Society of Urological Pathology expertâ€driven recommendations. Histopathology, 2018, 72, 893-904.	2.9	52
256	TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Modern Pathology, 2009, 22, 359-365.	5.5	51
257	Prostatic Ductal Adenocarcinoma: A Mini Review. Medical Principles and Practice, 2010, 19, 82-85.	2.4	51
258	Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate, 2013, 73, 1673-1680.	2.3	51
259	The significance of low-grade prostate cancer on needle biopsy. A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor. Cancer, 1990, 66, 1927-1932.	4.1	50
260	Variability in Diagnostic Opinion Among Pathologists for Single Small Atypical Foci in Prostate Biopsies. American Journal of Surgical Pathology, 2010, 34, 169-177.	3.7	50
261	Magnetic Resonanceâ€“invisible Versus Magnetic Resonanceâ€“visible Prostate Cancer in Active Surveillance: AÂPreliminary Report on Disease Outcomes. Urology, 2015, 85, 147-154.	1.0	50
262	The Significance of Intraluminal Crystalloids in Benign Prostatic Glands on Needle Biopsy. American Journal of Surgical Pathology, 1997, 21, 725-728.	3.7	50
263	Little or No Residual Prostate Cancer at Radical Prostatectomy: Vanishing Cancer or Switched Specimen?. American Journal of Surgical Pathology, 2005, 29, 467-473.	3.7	49
264	Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists. Human Pathology, 2006, 37, 292-297.	2.0	49
265	A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. Human Pathology, 2009, 40, 1693-1698.	2.0	49
266	Pathologic Stage of Prostatic Ductal Adenocarcinoma at Radical Prostatectomy. American Journal of Surgical Pathology, 2011, 35, 615-619.	3.7	49
267	Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Modern Pathology, 2015, 28, 446-456.	5.5	49
268	Updated Protocol for the Examination of Specimens From Patients With Carcinomas of the Prostate Gland. Archives of Pathology and Laboratory Medicine, 2006, 130, 936-946.	2.5	49
269	The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. , 1996, 78, 350-356.		48
270	Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in turp specimens. Urology, 1997, 49, 558-563.	1.0	48

#	Article	IF	Citations
271	Partial Atrophy on Prostate Needle Biopsy Cores: A Morphologic and Immunohistochemical Study. American Journal of Surgical Pathology, 2008, 32, 851-857.	3.7	48
272	TMPRSS2â€“ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Modern Pathology, 2009, 22, 1415-1422.	5.5	48
273	Diagnostic Challenges of Clonal Heterogeneity in Prostate Cancer. Journal of Clinical Oncology, 2015, 33, e38-e40.	1.6	48
274	Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer, 1992, 69, 511-519.	4.1	47
275	A Clinicopathologic Analysis of Urothelial Carcinomas Diagnosed on Prostate Needle Biopsy. American Journal of Surgical Pathology, 2001, 25, 794-801.	3.7	47
276	Atypia in inverted urothelial papillomas: Pathology and prognostic significance. Human Pathology, 2004, 35, 1499-1504.	2.0	47
277	The Relationship Between the Extent of Extraprostatic Extension and Survival Following Radical Prostatectomy. European Urology, 2015, 67, 342-346.	1.9	47
278	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precision Oncology, 2019, 3, 1-9.	3.0	47
279	A Quantitative Histological Analysis of the Dilated Ureter of Childhood. Journal of Urology, 1992, 148, 1482-1486.	0.4	46
280	Adenocarcinoma of the Colon Simulating Primary Urinary Bladder Neoplasia. American Journal of Surgical Pathology, 1993, 17, 171-178.	3.7	46
281	Ability to predict biochemical progression using gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology, 1996, 48, 685-691.	1.0	46
282	THE SIGNIFICANCE OF PRIOR BENIGN NEEDLE BIOPSIES IN MEN SUBSEQUENTLY DIAGNOSED WITH PROSTATE CANCER. Journal of Urology, 1999, 162, 1649-1652.	0.4	46
283	False Positive Labeling of Prostate Cancer With High Molecular Weight Cytokeratin: p63 a More Specific Immunomarker for Basal Cells. American Journal of Surgical Pathology, 2008, 32, 1890-1895.	3.7	46
284	Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings. European Urology Focus, 2017, 3, 457-466.	3.1	46
285	Positive Surgical Margins in Areas of Capsular Incision in Otherwise Organ-confined Disease at Radical Prostatectomy: Histologic Features and Pitfalls. American Journal of Surgical Pathology, 2008, 32, 1201-1206.	3.7	45
286	Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology, 2010, 42, 384-394.	0.6	45
287	Original Articles: Prostate Cancer: Deoxyribonucleic Acid Ploidy Analysis as a Predictor of Recurrence Following Radical Prostatectomy for Stage T2 Disease. Journal of Urology, 1995, 153, 1015-1019.	0.4	44
288	Differentiation of colonic metaplasia from adenocarcinoma of urinary bladder. Human Pathology, 1997, 28, 1152-1157.	2.0	44

#	Article	IF	Citations
289	Aberrant Expression of p63 in Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2013, 37, 1401-1406.	3.7	44
290	New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8â€“10 Prostate Cancer. European Urology, 2017, 71, 907-912.	1.9	44
291	Intraductal carcinoma of the prostate in the absence of highâ€grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. Journal of Pathology, 2019, 249, 79-89.	4.5	44
292	Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies. Human Pathology, 2005, 36, 480-485.	2.0	43
293	Recommendations for the reporting of prostate carcinoma. Human Pathology, 2007, 38, 1305-1309.e4.	2.0	43
294	Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. Journal of Urology, 2016, 195, 337-342.	0.4	43
295	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. European Urology, 2016, 69, 576-581.	1.9	42
296	The Relationship of Prostate Specific Antigen Levels and Residual Tumor Volume in Stage a Prostate Cancer. Journal of Urology, 1990, 144, 1167-1170.	0.4	41
297	Acidic mucin in the prostate: Can it differentiate adenosis from adenocarcinoma?. Human Pathology, 1992, 23, 1321-1325.	2.0	41
298	Perineural Involvement by Benign Prostatic Glands on Needle Biopsy. American Journal of Surgical Pathology, 2005, 29, 1159-1163.	3.7	41
299	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	2.8	41
300	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology, 2015, 67, 313-324.	2.9	41
301	Central zone histology of the prostate: A mimicker of high-grade prostatic intraepithelial neoplasia. Human Pathology, 2002, 33, 518-523.	2.0	40
302	Tubulocystic carcinoma of the kidney with poorly differentiated foci: a series of 3 cases with fluorescence in situ hybridization analysis. Human Pathology, 2013, 44, 1406-1411.	2.0	40
303	Haemangiomas in kidneys with end-stage renal disease: a novel clinicopathological association. Histopathology, 2014, 65, 309-318.	2.9	40
304	Diagnosis of Cowper's Glands on Prostate Needle Biopsy. American Journal of Surgical Pathology, 1997, 21, 550-555.	3.7	40
305	Foamy Gland High-Grade Prostatic Intraepithelial Neoplasia. American Journal of Surgical Pathology, 2000, 24, 140.	3.7	39
306	Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer, 2003, 98, 2583-2591.	4.1	39

#	Article	IF	Citations
307	Recommendations for the Reporting of Prostate Carcinoma. American Journal of Clinical Pathology, 2008, 129, 24-30.	0.7	39
308	Identification of Gleason Pattern 5 on Prostatic Needle Core Biopsy. American Journal of Surgical Pathology, 2011, 35, 1706-1711.	3.7	39
309	Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. Human Pathology, 2016, 47, 20-25.	2.0	39
310	Clinical implications of changing definitions within the Gleason grading system. Nature Reviews Urology, 2010, 7, 136-142.	3.8	38
311	Hepatocyte nuclear factorâ€“1Î² expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis. Human Pathology, 2011, 42, 1613-1619.	2.0	38
312	Immunohistochemical pitfalls in prostate pathology. Human Pathology, 2012, 43, 313-324.	2.0	38
313	When is Prostate Cancer Really Cancer?. Urologic Clinics of North America, 2014, 41, 339-346.	1.8	38
314	Renal oncocytoma with vascular invasion: a series of 22 cases. Human Pathology, 2016, 58, 1-6.	2.0	38
315	The Gleason Grading System: An Overview. Journal of Urologic Pathology, 1999, 10, 141-158.	0.3	38
316	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer, 2000, 89, 2577-2586.	4.1	37
317	Nonchoriocarcinomatous Trophoblastic Tumors of the Testis. American Journal of Surgical Pathology, 2015, 39, 1468-1478.	3.7	37
318	Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies. American Journal of Surgical Pathology, 2016, 40, 1686-1692.	3.7	37
319	Rare histological patterns of prostatic ductal adenocarcinoma. Pathology, 2010, 42, 319-324.	0.6	36
320	Prediction of patientâ€specific risk and percentile cohort risk of pathological stage outcome using continuous prostateâ€specific antigen measurement, clinical stage and biopsy Gleason score. BJU International, 2011, 107, 1562-1569.	2.5	36
321	Changes in prostate cancer grading: Including a new patientâ€centric grading system. Prostate, 2016, 76, 427-433.	2.3	36
322	Cell Orientation Entropy (COrE): Predicting Biochemical Recurrence from Prostate Cancer Tissue Microarrays. Lecture Notes in Computer Science, 2013, 16, 396-403.	1.3	36
323	High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 34.e27-34.e32.	1.6	35
324	PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. Prostate, 2015, 75, 1610-1619.	2.3	35

#	Article	IF	Citations
325	Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. Annals of Diagnostic Pathology, 2015, 19, 301-305.	1.3	35
326	Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology, 2006, 67, 115-119.	1.0	34
327	High-grade Foamy Gland Prostatic Adenocarcinoma on Biopsy or Transurethral Resection. American Journal of Surgical Pathology, 2009, 33, 583-590.	3.7	34
328	Epithelial Proliferations in Prostatic Stromal Tumors of Uncertain Malignant Potential (STUMP). American Journal of Surgical Pathology, 2011, 35, 898-903.	3.7	34
329	A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma. Human Pathology, 2015, 46, 1204-1208.	2.0	34
330	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. American Journal of Surgical Pathology, 2018, 42, 1571-1584.	3.7	34
331	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. Ca-A Cancer Journal for Clinicians, 2016, 66, 408-436.	329.8	33
332	Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Research, 2017, 7, 80.	2.5	33
333	CAN PLOIDY OF PROSTATE CARCINOMA DIAGNOSED ON NEEDLE BIOPSY PREDICT RADICAL PROSTATECTOMY STAGE AND GRADE?. Journal of Urology, 1999, 162, 2036-2039.	0.4	32
334	Bladder cancer, pathological classification and staging. BJU International, 2008, 102, 1216-1220.	2.5	32
335	Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features. Human Pathology, 2008, 39, 543-549.	2.0	32
336	Conditional Probability of Reclassification in an Active Surveillance Program for Prostate Cancer. Journal of Urology, 2015, 193, 1950-1955.	0.4	32
337	Contemporary Gleason grading and novel Grade Groups in clinical practice. Current Opinion in Urology, 2016, 26, 488-492.	1.8	32
338	Grading of Prostate Cancer: Past, Present, and Future. Current Urology Reports, 2016, 17, 25.	2.2	32
339	Inverted Papillomas of the Prostatic Urethra. American Journal of Surgical Pathology, 2006, 30, 975-979.	3.7	31
340	Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases. Human Pathology, 2012, 43, 2124-2128.	2.0	31
341	Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital. Urology, 2015, 86, 539-543.	1.0	31
342	The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. Human Pathology, 2016, 54, 184-188.	2.0	31

#	Article	IF	Citations
343	Differential Diagnosis of Intraductal Lesions of the Prostate. American Journal of Surgical Pathology, 2016, 40, e67-e82.	3.7	31
344	Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features. American Journal of Surgical Pathology, 2018, 42, 1286-1296.	3.7	31
345	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2020, 44, 673-680.	3.7	31
346	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. Journal of Urology, 2001, 165, 864-866.	0.4	30
347	Inverted (Hobnail) High-Grade Prostatic Intraepithelial Neoplasia (PIN). American Journal of Surgical Pathology, 2001, 25, 1534-1539.	3.7	30
348	Prognostic significance of atypical papillary urothelial hyperplasia. Human Pathology, 2002, 33, 512-517.	2.0	30
349	Diagnosis of limited adenocarcinoma of the prostate. Histopathology, 2012, 60, 28-40.	2.9	30
350	Intestinal metaplasia of the bladder with dysplasia: a risk factor for carcinoma?. Histopathology, 2015, 67, 325-330.	2.9	30
351	Infarct of the Prostate Gland. American Journal of Surgical Pathology, 2000, 24, 1378-1384.	3.7	29
352	PATIENT AND UROLOGIST DRIVEN SECOND OPINION OF PROSTATE NEEDLE BIOPSIES. Journal of Urology, 2005, 174, 1390-1394.	0.4	29
353	Detection of Residual Tumor Cells in Bladder Biopsy Specimens: Pitfalls in the Interpretation of Cytokeratin Stains. American Journal of Surgical Pathology, 2007, 31, 390-397.	3.7	29
354	Significance of Prostate Adenocarcinoma Perineural Invasion on Biopsy in Patients Who are Otherwise Candidates for Active Surveillance. Journal of Urology, 2011, 186, 470-473.	0.4	29
355	Should Gleason 6 be labeled as cancer?. Current Opinion in Urology, 2015, 25, 238-245.	1.8	29
356	Risk prediction tool for grade reâ€classification in men with favourableâ€risk prostate cancer on active surveillance. BJU International, 2017, 120, 25-31.	2.5	29
357	The Lower Urinary Tract and Male Genital System. , 2010, , 971-1004.		29
358	Lesions missed on prostate biopsies in cases sent in for consultation. Prostate, 2003, 54, 310-314.	2.3	28
359	Urothelial carcinoma with abundant myxoid stroma. Human Pathology, 2009, 40, 1391-1398.	2.0	28
360	Variant of prostatic adenocarcinoma with Paneth cellâ€“like neuroendocrine differentiation readily misdiagnosed as Gleason pattern 5. Human Pathology, 2014, 45, 2388-2393.	2.0	28

#	Article	IF	Citations
361	Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer. Journal of Urology, 2014, 191, 629-637.	0.4	28
362	Selective invocation of shape priors for deformable segmentation and morphologic classification of prostate cancer tissue microarrays. Computerized Medical Imaging and Graphics, 2015, 41, 3-13.	5.8	28
363	Carcinoma of the Uterine Cervix Involving the Genitourinary Tract. American Journal of Surgical Pathology, 2016, 40, 27-35.	3.7	28
364	The effect of limited (tertiary) Gleason pattern 5 on the new prostate cancer grade groups. Human Pathology, 2017, 63, 27-32.	2.0	28
365	Myxoid malignant fibrous histiocytoma of the bladder. Cancer, 1990, 66, 1836-1842.	4.1	27
366	Diagnoses rendered on prostate needle biopsy in community hospitals. , 1998, 35, 50-55.		27
367	Invasive Low-Grade Papillary Urothelial Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1081-1086.	3.7	27
368	Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan. Prostate, 2014, 74, 321-325.	2.3	27
369	Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance. Journal of Urology, 2018, 199, 1482-1487.	0.4	27
370	Features and Prognostic Significance of Intraductal Carcinoma of the Prostate. European Urology Oncology, 2018, 1, 21-28.	5.4	27
371	Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?. Journal of Urology, 2002, 167, 2440-2.	0.4	27
372	Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. Urology, 2002, 60, 666-669.	1.0	26
373	What???s new in prostate cancer disease assessment in 2006?. Current Opinion in Urology, 2006, 16, 146-151.	1.8	26
374	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	3.8	26
375	Head to head: should the intraductal component of invasive prostate cancer be graded?. Histopathology, 2021, 78, 231-239.	2.9	26
376	Atypical Cribriform Lesions on Prostate Biopsy. American Journal of Surgical Pathology, 2001, 25, 147-155.	3.7	25
377	Detection of Cancer in Radical Prostatectomy Specimens With no Residual Carcinoma in the Initial Review of Slides. American Journal of Surgical Pathology, 2009, 33, 120-125.	3.7	25
378	Pseudopapillary Features in Prostatic Adenocarcinoma Mimicking Urothelial Carcinoma. American Journal of Surgical Pathology, 2014, 38, 941-945.	3.7	25

#	Article	IF	Citations
379	Prostate Cancer Grading. American Journal of Surgical Pathology, 2016, 40, 137.	3.7	25
380	Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance. BJU International, 2020, 126, 373-378.	2.5	25
381	Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World Journal of Urology, 1997, 15, 373-377.	2.2	24
382	Fragmentation of prostatic needle biopsy cores containing adenocarcinoma: the role of specimen submission. BJU International, 2010, 105, 172-175.	2.5	24
383	CLINICAL SIGNIFICANCE OF DENUDED UROTHELIUM IN BLADDER BIOPSY. Journal of Urology, 2001, 166, 457-460.	0.4	23
384	Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. Prostate, 2007, 67, 1202-1210.	2.3	23
385	Diffuse Adenosis of the Peripheral Zone in Prostate Needle Biopsy and Prostatectomy Specimens. American Journal of Surgical Pathology, 2008, 32, 1360-1366.	3.7	23
386	Frozen section during partial nephrectomy: does it predict positive margins?. BJU International, 2015, 116, 868-872.	2.5	23
387	Definition of Insignificant Tumor Volume of Gleason Score 3 + 3 = 6 (Grade Group 1) Prostate Cancer at Radical Prostatectomyâ€”Is it Time to Increase the Threshold?. Journal of Urology, 2016, 196, 1664-1669.	0.4	23
388	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	3.7	22
389	Neuroendocrine differentiation in usualâ€type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate, 2020, 80, 1012-1023.	2.3	22
390	Is high-grade prostatic intraepithelial neoplasia on needle biopsy different in an Asian population: A clinicopathologic study performed in Singapore. Urology, 2006, 68, 800-803.	1.0	21
391	Prognostic value of Herâ€2/neu and DNA index for progression, metastasis and prostate cancerâ€specific death in men with longâ€term followâ€up after radical prostatectomy. International Journal of Cancer, 2008, 123, 2636-2643.	5.1	21
392	Initial High-grade Prostatic Intraepithelial Neoplasia With Carcinoma on Subsequent Prostate Needle Biopsy. American Journal of Surgical Pathology, 2011, 35, 1165-1167.	3.7	21
393	Pseudocarcinomatous Urothelial Hyperplasia of the Bladder: Clinical Findings and Followup of 70 Patients. Journal of Urology, 2013, 189, 2083-2086.	0.4	21
394	Pathological characteristics of low risk prostate cancer based on totally embedded prostatectomy specimens. Prostate, 2015, 75, 424-429.	2.3	21
395	Gleason pattern 4 with cribriform morphology on biopsy is associated with adverse clinicopathological findings in a prospective radical prostatectomy cohort. Human Pathology, 2020, 98, 74-80.	2.0	21
396	Advances in the selection of patients with prostate cancer for active surveillance. Nature Reviews Urology, 2021, 18, 197-208.	3.8	21

#	Article	IF	Citations
397	Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. Journal of Urology, 2021, 205, 1069-1074.	0.4	21
398	Carcinosarcomas: tumors in transition?. Histology and Histopathology, 2015, 30, 673-87.	0.7	21
399	Inverted urothelial papillomas with foamy or vacuolated cytoplasm. Human Pathology, 2006, 37, 1577-1582.	2.0	20
400	Gleason Pattern 5 is Frequently Underdiagnosed on Prostate Needle-core Biopsy. Urology, 2012, 79, 178-181.	1.0	20
401	Chromosomal abnormalities of highâ€grade mucinous tubular and spindle cell carcinoma of the kidney. Histopathology, 2017, 71, 719-724.	2.9	20
402	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	4.3	20
403	Significance of Denuded Urothelium in Papillary Urothelial Lesions. American Journal of Surgical Pathology, 2007, 31, 298-303.	3.7	19
404	Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center. Human Pathology, 2011, 42, 1799-1803.	2.0	19
405	Common chromosomal aberrations detected by array comparative genomic hybridization in specialized stromal tumors of the prostate. Modern Pathology, 2013, 26, 1536-1543.	5.5	19
406	Ureteral and Urethral Frozen Sections During Radical Cystectomy or Cystoprostatectomy: An Analysis of Denudation and Atypia. Urology, 2014, 84, 619-623.	1.0	19
407	African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance. Journal of Urology, 2016, 195, 301-306.	0.4	19
408	Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. BJU International, 2020, 125, 861-866.	2.5	19
409	Characterization of prostatic basal cell hyperplasia and neoplasia in aged macaques: Comparative pathology in human and nonhuman primates. , 1996, 29, 51-59.		18
410	AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy. Prostate, 2012, 72, 1133-1139.	2.3	18
411	Rosaiâ€Dorfman disease of the genitoâ€urinary tract: analysis of six cases from the testis and kidney. Histopathology, 2014, 65, 908-916.	2.9	18
412	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 2016, 69, 186-190.	1.9	18
413	Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract. Human Pathology, 2017, 67, 152-159.	2.0	18
414	Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy. Nature Reviews Urology, 2018, 15, 55-66.	3.8	18

#	Article	IF	Citations
415	Small cellâ€“like change in prostatic intraepithelial neoplasia, intraductal carcinoma, and invasive prostatic carcinoma: a study of 7 cases. Human Pathology, 2013, 44, 427-431.	2.0	17
416	Nephrogenic Adenoma. American Journal of Surgical Pathology, 2013, 37, 532-538.	3.7	17
417	A new contemporary prostate cancer grading system. Annales De Pathologie, 2015, 35, 474-476.	0.1	17
418	Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors. Prostate, 2017, 77, 681-685.	2.3	17
419	PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall. Human Pathology, 2019, 94, 11-15.	2.0	17
420	Computer Extracted Features from Initial H&E Tissue Biopsies Predict Disease Progression for Prostate Cancer Patients on Active Surveillance. Cancers, 2020, 12, 2708.	3.7	17
421	Lipomeningioma: Report of Three Cases and Review of the Literature. Neurosurgery, 1989, 25, 122-126.	1.1	16
422	Primary intracerebral small-cell osteosarcoma in an adolescent girl: report of a case. Journal of Neuro-Oncology, 1997, 32, 169-174.	2.9	16
423	ANALYSIS OF THE PROSTATIC CENTRAL ZONE IN PATIENTS WITH UNILATERAL ABSENCE OF WOLFFIAN DUCT STRUCTURES: FURTHER EVIDENCE OF THE MESODERMAL ORIGIN OF THE PROSTATIC CENTRAL ZONE. Journal of Urology, 1998, 160, 2126-2129.	0.4	16
424	Negative 34Î²E12 staining in a small focus of atypical glands on prostate needle biopsy: a follow-up study of 332 cases. Human Pathology, 2004, 35, 43-46.	2.0	16
425	Diagnosis and Classification of Flat, Papillary, and Invasive Urothelial Carcinoma: The WHO/ISUP Consensus. International Journal of Surgical Pathology, 2010, 18, 106-111.	0.8	16
426	Symplastic Leiomyomas of the Scrotum. American Journal of Surgical Pathology, 2014, 38, 1410-1417.	3.7	16
427	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e235-e245.	3.8	16
428	Pericytic tumors of the kidneyâ€”a clinicopathologic analysis of 17 cases. Human Pathology, 2017, 64, 106-117.	2.0	16
429	Prognostic significance of extensive necrosis in renal cell carcinoma. Human Pathology, 2017, 66, 108-114.	2.0	16
430	Intraoperative Consultation and Macroscopic Handling. American Journal of Surgical Pathology, 2018, 42, e33-e43.	3.7	16
431	Mimickers of urothelial neoplasia. Annals of Diagnostic Pathology, 2019, 38, 11-19.	1.3	16
432	SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours. Histopathology, 2020, 76, 550-559.	2.9	16

#	Article	IF	Citations
433	Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care. Journal of Clinical Oncology, 2022, 40, 3106-3109.	1.6	16
434	Diffuse leptomeningeal seeding from a malignant spinal cord astrocytoma in a child with neurofibromatosis. Journal of Neuro-Oncology, 1986, 4, 159-163.	2.9	15
435	Prediction of significant cancer in men with stage Tic adenocarcinoma of the prostate. World Journal of Urology, 1997, 15, 359-363.	2.2	15
436	Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy. Human Pathology, 2004, 35, 281-289.	2.0	15
437	Correlation of High Body Mass Index With More Advanced Localized Prostate Cancer at Radical Prostatectomy Is Not Reflected in PSA Level and PSA Density but Is Seen in PSA Mass. American Journal of Clinical Pathology, 2015, 144, 271-277.	0.7	15
438	Average Weight of Seminal Vesicles. International Journal of Surgical Pathology, 2015, 23, 617-622.	0.8	15
439	A subset of fat-predominant angiomyolipomas label for MDM2 : a potential diagnostic pitfall. Human Pathology, 2016, 57, 7-12.	2.0	15
440	Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy. Journal of Urology, 2018, 200, 1068-1074.	0.4	15
441	DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giantâ€cell features. Histopathology, 2019, 74, 836-843.	2.9	15
442	Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma. Modern Pathology, 2021, 34, 445-456.	5.5	15
443	Number and location of nucleoli and presence of apoptotic bodies in diagnostically challenging cases of prostate adenocarcinoma on needle biopsy. Human Pathology, 2005, 36, 1172-1177.	2.0	14
444	Computer aided analysis of prostate histopathology images Gleason grading especially for Gleason score 7. , 2015, 2015, 3013-6.		14
445	Gleason score 5â€¯+â€¯3â€¯=â€¯8 (grade group 4) prostate cancerâ€”a rare occurrence with contemporary grading. Human Pathology, 2020, 97, 40-51.	2.0	14
446	Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. International Journal of Cancer, 1999, 84, 594-597.	5.1	13
447	Update on the Gleason grading system. Annales De Pathologie, 2011, 31, S20-S26.	0.1	13
448	Adenocarcinoma of the Prostate with Gleason Score 9-10 on Core Biopsy: Correlation with Findings at Radical Prostatectomy and Prognosis. Journal of Urology, 2013, 190, 2068-2073.	0.4	13
449	Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance. Urology, 2015, 86, 991-997.	1.0	13
450	A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1864-1872.	2.5	13

#	Article	IF	Citations
451	Î”Np63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Human Pathology, 2015, 46, 384-389.	2.0	13
452	Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 532.e1-532.e6.	1.6	13
453	Round cell pattern of prostatic stromal tumor of uncertain malignant potential: a subtle newly recognized variant. Human Pathology, 2016, 52, 68-73.	2.0	13
454	Safety and Feasibility of Direct Magnetic Resonance Imaging-guided Transperineal Prostate Biopsy Using a Novel Magnetic Resonance Imaging-safe Robotic Device. Urology, 2017, 109, 216-221.	1.0	13
455	Significance of Gleason Score 7 With Tertiary Pattern 5 at Radical Prostatectomy. Urology, 2017, 100, 175-179.	1.0	13
456	Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series. BJU International, 2017, 119, 444-448.	2.5	13
457	ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. Prostate, 2018, 78, 896-904.	2.3	13
458	RNA Expression Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder Reveals a Basal-Like Molecular Subtype. American Journal of Pathology, 2020, 190, 134-144.	3.8	13
459	Cardinal Multiridgelet-based Prostate Cancer Histological Image Classification for Gleason Grading. , 2011, , .		12
460	Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience. Clinical Genitourinary Cancer, 2015, 13, 435-440.	1.9	12
461	An expanded immunohistochemical profile of osteoclast-rich undifferentiated carcinoma of the urinary tract. Modern Pathology, 2018, 31, 984-988.	5.5	12
462	PIN-like (Ductal) Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2018, 42, 1693-1700.	3.7	12
463	Gastrointestinal Malakoplakia. American Journal of Surgical Pathology, 2020, 44, 1251-1258.	3.7	12
464	Current and proposed biologic markers in prostate cancer. Journal of Cellular Biochemistry, 1992, 50, 65-67.	2.6	11
465	Minute Foci of Gleason Score 8-10 on Prostatic Needle Biopsy. American Journal of Surgical Pathology, 2005, 29, 962-968.	3.7	11
466	Skeletal Muscle Involvement by Limited Gleason Score 6 Adenocarcinoma of the Prostate on Needle Biopsy is Not Associated With Adverse Findings at Radical Prostatectomy. Journal of Urology, 2010, 184, 2308-2312.	0.4	11
467	Small blue cells mimicking small cell carcinoma in spermatocele and hydrocele specimens: a report of 5 cases. Human Pathology, 2010, 41, 88-93.	2.0	11
468	Idiopathic granulomatous orchitis: morphology and evaluation of its relationship to IgG4 related disease. Human Pathology, 2014, 45, 844-850.	2.0	11

#	Article	IF	Citations
469	Prostate-specific Antigen Mass Densityâ€"A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution. Urology, 2016, 90, 141-147.	1.0	11
470	Pathological Findings in Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy: Relation to Prostate Cancer Focal Therapy. Urology, 2017, 105, 18-23.	1.0	11
471	Improving the evaluation and diagnosis of clinically significant prostate cancer. Current Opinion in Urology, 2017, 27, 191-197.	1.8	11
472	Metastatic potential to regional lymph nodes with Gleason score â‰¤7, including tertiary pattern 5, at radical prostatectomy. BJU International, 2017, 119, 872-878.	2.5	11
473	Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance. Journal of Urology, 2018, 199, 954-960.	0.4	11
474	Clear Cell Adenocarcinoma in Men. American Journal of Surgical Pathology, 2021, 45, 270-276.	3.7	11
475	Understanding PSA and its derivatives in prediction of tumor volume: addressing health disparities in prostate cancer risk stratification. Oncotarget, 2017, 8, 20802-20812.	1.8	11
476	Is Grade Group 1 (Gleason score 3â€Š+â€Š3â€Š=â€Š6) adenocarcinoma of the prostate really cancer?. Current Opinion in Urology, 2022, 32, 91-95.	1.8	11
477	Initial Atypical Diagnosis With Carcinoma on Subsequent Prostate Needle Biopsy: Findings at Radical Prostatectomy. Journal of Urology, 2010, 184, 1953-1957.	0.4	10
478	Diagnostic dilemmas in enlarged and diffusely hemorrhagic adrenal glands. Human Pathology, 2016, 53, 63-72.	2.0	10
479	The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. Journal of Urology, 2017, 197, 1060-1067.	0.4	10
480	Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6. American Journal of Clinical Pathology, 2021, 155, 588-596.	0.7	10
481	Benign Mimickers of Prostate Adenocarcinoma on Needle Biopsy and Transurethral Resection. Surgical Pathology Clinics, 2008, 1, 1-41.	1.7	9
482	Predicting the Risk of Nonâ€"organ-confined Prostate Cancer When Perineural Invasion Is Found on Biopsy. Urology, 2014, 83, 1117-1121.	1.0	9
483	Re: Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer. Pathology, 2015, 47, 394.	0.6	9
484	International Society of Urological Pathology (ISUP) Grading of Prostate Cancer: Author's Reply. American Journal of Surgical Pathology, 2016, 40, 862-864.	3.7	9
485	Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 (Grade Group 1) Prostate Cancer?. Journal of Urology, 2016, 196, 1659-1663.	0.4	9
486	Sarcomatoid carcinoma associated with small cell carcinoma of the urinary bladder: a series of 28 cases. Human Pathology, 2017, 67, 169-175.	2.0	9

#	Article	IF	Citations
487	PINâ€like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations. Histopathology, 2021, 78, 327-333.	2.9	9
488	Immunoreactivity for prostate-specific antigen and prostatic acid phosphatase in adenocarcinoma of the prostate: Relation to progression following radical prostatectomy. , 1998, 34, 29-33.		8
489	Tubular adenoma of the urinary tract: a newly described entity. Human Pathology, 2013, 44, 1890-1894.	2.0	8
490	Active surveillance for prostate cancer: the role of the pathologist. Pathology, 2015, 47, 1-3.	0.6	8
491	How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016â€“2017. European Urology, 2019, 75, 25-31.	1.9	8
492	Downgrading of grade group 2 intermediateâ€risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance. Cancer, 2020, 126, 1632-1639.	4.1	8
493	Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging. Reviews in Urology, 2017, 19, 77-88.	0.9	8
494	Transitional Cell Carcinoma of the Bladder in an Adolescent with Turnerâ€™s Syndrome. Journal of Urology, 1987, 137, 398-400.	0.4	7
495	Recommendations for the reporting of prostate carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 751-756.	2.8	7
496	Mimickers of Prostatic Intraepithelial Neoplasia. International Journal of Surgical Pathology, 2010, 18, 142-148.	0.8	7
497	Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy. BJU International, 2013, 111, E306-E309.	2.5	7
498	Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma. Human Pathology, 2015, 46, 554-557.	2.0	7
499	Smooth muscle and adenoma-like renal tumor: a previously unreported variant of mixed epithelial stromal tumor or a distinctive renal neoplasm?. Human Pathology, 2015, 46, 894-905.	2.0	7
500	Invasive low-grade papillary urothelial carcinoma: an immunohistochemical study of 26 cases. Human Pathology, 2015, 46, 1836-1841.	2.0	7
501	Prevalence and distribution of 15 high-risk human papillomavirus types in squamous cell carcinoma of the scrotum. Human Pathology, 2016, 53, 130-136.	2.0	7
502	Does the distance between tumor and margin in radical prostatectomy specimens correlate with prognosis: relation to tumor location. Human Pathology, 2016, 56, 11-15.	2.0	7
503	In response to â€˜a plea for greater standardizationâ€™ in intraductal carcinoma of the prostate: greater standardization requires greater evidence. Histopathology, 2017, 70, 1011-1013.	2.9	7
504	Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma. American Journal of Surgical Pathology, 2021, 45, 450-462.	3.7	7

#	Article	IF	Citations
505	Multiphoton Microscopy for Identifying Collagen Signatures Associated with Biochemical Recurrence in Prostate Cancer Patients. Journal of Personalized Medicine, 2021, 11, 1061.	2.5	7
506	Needle Biopsy of Recurrent Adenocarcinoma of the Prostate After Radical Prostatectomy. Modern Pathology, 2000, 13, 521-527.	5.5	6
507	Radical Prostatectomy: Processing, Staging, and Prognosis. Parts I and II. International Journal of Surgical Pathology, 2010, 18, 118-123.	0.8	6
508	Immunohistology of the Prostate, Bladder, Kidney, and Testis. , 2011, , 593-661.		6
509	Two Sequential Diagnoses of Atypical Foci Suspicious for Carcinoma on Prostate Biopsy: A Follow-up Study of 179 Cases. Urology, 2013, 82, 861-864.	1.0	6
510	New prostate cancer grade group system correlates with prostate cancer death in addition to biochemical recurrence. British Journal of Cancer, 2016, 114, 1069-1070.	6.4	6
511	Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease. Journal of Urology, 2017, 198, 608-613.	0.4	6
512	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. Human Pathology, 2019, 94, 58-63.	2.0	6
513	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	1.6	6
514	Mandatory second opinion surgical pathology at a large referral hospital. Cancer, 1999, 86, 2426-2435.	4.1	6
515	Intraductal Adenocarcinoma of the Prostate With Cribriform or Papillary Ductal Morphology. American Journal of Surgical Pathology, 2022, 46, 233-240.	3.7	6
516	Significance of Paneth cellâ€“like differentiation in prostatic adenocarcinoma: a retrospective cohort study of 80 cases. Human Pathology, 2020, 102, 7-12.	2.0	6
517	Fine-needle core and aspiration biopsy. A new method for diagnosis of prostatic carcinoma. Cancer, 1990, 63, 1846-1855.	4.1	5
518	The FAQ Initiative Explaining Pathology Reports to Patients. American Journal of Surgical Pathology, 2010, 34, 1058-1060.	3.7	5
519	Testicular Swelling Due to Lymphatic Filariasis After Brief Travel to Haiti. American Journal of Tropical Medicine and Hygiene, 2014, 91, 89-91.	1.4	5
520	Value of Transition Zone Biopsy in Active Surveillance of Prostate Cancer. Journal of Urology, 2014, 191, 1755-1759.	0.4	5
521	Risk Factors for Intraprostatic Incision into Malignant Glands at Radical Prostatectomy. European Urology, 2015, 68, 311-316.	1.9	5
522	Re: Clinical significance of prospectively assigned gleason tertiary pattern 4 in contemporary Gleason score 3â€‰+â€‰3â€‰=â€‰6 prostate cancer. Prostate, 2016, 76, 1130-1131.	2.3	5

#	Article	IF	Citations
523	Urology journals recommend new prostate cancer grade groups. Nature Reviews Urology, 2016, 13, 374-375.	3.8	5
524	Latest Novelties on the World Health Organization Morphological Classifications of Genitourinary Cancers. European Urology Supplements, 2017, 16, 199-209.	0.1	5
525	Granular Cell Tumor of the Bladder: A Report of Six Cases. Urology, 2018, 121, 203.e1-203.e5.	1.0	5
526	Plasmacytoid acinar adenocarcinoma of the prostate: a newly described variant of prostate cancer. Human Pathology, 2019, 94, 86-91.	2.0	5
527	Well-differentiated neuroendocrine tumors of the lower urinary tract: biologic behavior of a rare entity. Human Pathology, 2021, 109, 53-58.	2.0	5
528	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. Human Pathology, 2020, 101, 70-79.	2.0	5
529	Pathology of Prostatic Neoplasia. , 2012, , 2726-2734.e3.		5
530	Curvelet-based classification of prostate cancer histological images of critical Gleason scores. , 2015, , .		4
531	Prostate Cancer Grade Groups Correlate with Prostate-specific Cancer Mortality: SEER Data for Contemporary Graded Specimens. European Urology, 2017, 71, 764-765.	1.9	4
532	Whole-exome sequencing demonstrates recurrent somatic copy number alterations and sporadic mutations in specialized stromal tumors of the prostate. Human Pathology, 2018, 76, 9-16.	2.0	4
533	Is There Enough Support for a New Prostate Grading System Factoring in Intraductal Carcinoma and Cribriform Cancer?. European Urology, 2020, 77, 199-200.	1.9	4
534	Fungal prostatitis due to endemic mycoses and Cryptococcus : A multicenter case series. Prostate, 2020, 80, 1006-1011.	2.3	4
535	Urothelial Differences in the Exstrophy-Epispadias Complex: Potential Implications for Management. Journal of Urology, 2021, 205, 1460-1465.	0.4	4
536	Workgroup 5: Assessment of prostate carcinoma in core needle biopsyâ€â€Definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer, 1996, 78, 376-381.	4.1	4
537	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
538	Mesenchymal Tumors of the Prostate. Surgical Pathology Clinics, 2008, 1, 105-128.	1.7	3
539	The Symphonyâ„¢ protocol for H&E staining of prostatic adenocarcinoma on needle biopsy: a multicentre analysis of 120 cases. Pathology, 2008, 40, 450-456.	0.6	3
540	Diagnostic issues of prostate biopsies. Case 6. PIN-like ductal adenocarcinoma. Annales De Pathologie, 2012, 32, 132-136.	0.1	3

#	Article	IF	Citations
541	Radical Prostatectomy Findings in Men on Active Surveillance: Variable Findings Dependent on Reason for Surgery and Entry Criteria. Journal of Urology, 2015, 194, 685-689.	0.4	3
542	Curvelet-based texture classification of critical Gleason patterns of prostate histological images. , 2016, , .		3
543	In Reply. Archives of Pathology and Laboratory Medicine, 2017, 141, 183-184.	2.5	3
544	A Comparison of Genitourinary Pathology Society (GUPS) and International Society of Urological Pathology (ISUP) Prostate Cancer Grading Guidelines. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 1005-1007.	3.7	3
545	Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. International Journal of Cancer, 2000, 89, 514-518.	5.1	3
546	A multinational phase III adjuvant study of immediate (I) versus deferred (D) chemotherapy (C)/hormone therapy (HT) after radical prostatectomy (RP): TAX-3501.. Journal of Clinical Oncology, 2012, 30, 4570-4570.	1.6	3
547	Pathological characterization and clinical outcome of penile intraepithelial neoplasia variants: a North American series. Modern Pathology, 2022, , .	5.5	3
548	Grading of Prostate Cancer in the 21St Century. Urologia, 2016, 83, 1-3.	0.7	2
549	Prognostic value of prostate biopsy grade: forever a product of sampling. BJU International, 2017, 119, 5-7.	2.5	2
550	Polypoid urothelial tumor with inverted growth pattern in the renal pelvis: morphologic and molecular characteristics of a unique diagnostic entity. Human Pathology, 2017, 59, 26-33.	2.0	2
551	Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Urology, 2020, 138, 84-90.	1.0	2
552	Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results. World Journal of Urology, 2020, 38, 3101-3111.	2.2	2
553	A webâ€based tutorial improves practicing pathologists' Gleason grading of images of prostate carcinoma specimens obtained by needle biopsy. Cancer, 2000, 89, 1818-1823.	4.1	2
554	Molecular Characterization of Metanephric Adenoma, Epithelial Wilms Tumor, and Overlap Lesions: An Integrated Whole-exome and Transcriptome Sequencing Analysis. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 257-263.	1.2	2
555	Does tertiary Gleason score 5 have prognostic significance in men with prostate cancer?. Nature Reviews Urology, 2008, 5, 250-251.	1.4	1
556	Editorial Comment. Journal of Urology, 2016, 196, 1081-1081.	0.4	1
557	Should the involvement of skeletal muscle by prostatic adenocarcinoma be reported on biopsies?. Human Pathology, 2016, 49, 10-14.	2.0	1
558	Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8â€“10 Prostate Cancer. Eur Urol 2017;71:907â€“12. European Urology, 2017, 72, e11-e12.	1.9	1

#	Article	IF	Citations
559	Advance on curvelet application to prostate cancer tissue image classification. , 2017, , .		1
560	Intraductal carcinoma of the prostate does not always represent invasive highâ€grade carcinoma extending into ducts. Histopathology, 2021, 78, 345-346.	2.9	1
561	Noninvasive low-grade papillary urothelial carcinoma with degenerative nuclear atypia: a grading pitfall. Human Pathology, 2021, 113, 1-8.	2.0	1
562	Reexamining the molecular findings in specialized stromal tumors of the prostate. Modern Pathology, 2021, 34, 2080-2081.	5.5	1
563	CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture. Prostate, 1998, 34, 162-168.	2.3	1
564	Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer. , 1984, 54, 1666.		1
565	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer, 2000, 89, 2577-2586.	4.1	1
566	Gleason 6 Tumors Should Still Be Labeled as Cancer. Current Clinical Urology, 2018, , 41-52.	0.0	1
567	Genomic characterization of ductal adenocarcinoma of the prostate.. Journal of Clinical Oncology, 2018, 36, 5030-5030.	1.6	1
568	Neoplasms of the Prostate and Seminal Vesicles. , 2007, , 56-108.		1
569	Evaluation of early clinical experience of a novel prognostic proteomics prostate cancer biopsy test.. Journal of Clinical Oncology, 2015, 33, 88-88.	1.6	1
570	Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2022, Publish Ahead of Print, .	3.7	1
571	Author reply. Cancer, 2000, 89, 226-226.	4.1	0
572	Genitourinary pathology in the new millennium. Pathology, 2010, 42, 317-318.	0.6	0
573	Editorial Comment. Urology, 2013, 82, 152-153.	1.0	0
574	Once again <scp>G</scp>leason remains the grading system to beat: a comparison with using percentage pattern 4/5. BJU International, 2014, 113, 353-354.	2.5	0
575	Editorial Comment. Urology, 2014, 83, 32.	1.0	0
576	Re: Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal of Urology, 2014, 191, 559-561.	0.4	0

#	Article	IF	Citations
577	Editorial Comment. Journal of Urology, 2014, 192, 102-102.	0.4	0
578	Current Gleason score 3Â+Â4Â=Â7: has it lost its significance compared with its historical counterpart?. BJU International, 2016, 117, 853-854.	2.5	0
579	Central pathology review of radical prostatectomy specimens does make a difference not only with grade. BJU International, 2017, 120, E5-E6.	2.5	0
580	Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancerâ€"Reply. JAMA Oncology, 2018, 4, 1133.	7.1	0
581	Plasma cell neoplasms of the bladder: a series of 9 cases. Human Pathology, 2021, 111, 52-58.	2.0	0
582	Very lowâ€risk versus lowâ€risk prostate cancer: A distinction worth keeping. Prostate, 2021, 81, 923-925.	2.3	0
583	SS8 Active surveillance for men with newly diagnosed prostate cancer : critical role of pathology. Japanese Journal of Urology, 2011, 102, 86.	0.1	0
584	Sarcomatoid carcinoma of the prostate: A case series from Johns Hopkins Hospital.. Journal of Clinical Oncology, 2015, 33, e16105-e16105.	1.6	0
585	Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease.. Journal of Clinical Oncology, 2016, 34, 51-51.	1.6	0
586	Computer extracted nuclear features from Feulgen and H&E images to predict biochemical recurrence in prostate cancer patients following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 5067-5067.	1.6	0
587	Computer extracted features on H&E images to improve biochemical recurrence prediction of Kattan nomogram for prostate cancer patients following radical prostatectomy: Preliminary findings.. Journal of Clinical Oncology, 2016, 34, 11556-11556.	1.6	0
588	Comparison of biochemical recurrence-free survival after radical prostatectomy among men in active surveillance following grade reclassification and men newly diagnosed with similar grade disease.. Journal of Clinical Oncology, 2017, 35, 117-117.	1.6	0
589	Comparison of biochemical recurrence free survival after radical prostatectomy triggered by grade reclassification on active surveillance, and men newly diagnosed with similar grade disease.. Journal of Clinical Oncology, 2017, 35, 5047-5047.	1.6	0
590	Editorial Comment. Journal of Urology, 2019, 201, 540-540.	0.4	0
591	Critical issues in grading of adenocarcinomas of the prostate. Canadian Journal of Urology, 1997, 4, 28-33.	0.0	0
592	Verrucous Squamous Hyperplasia of the Urinary Bladder. Archives of Pathology and Laboratory Medicine, 2022, , .	2.5	0